Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
Allena Pharmaceuticals, Inc. (ALNA)
Last allena pharmaceuticals, inc. earnings: 3/16 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.allenapharma.com/investor-relations
Company Research
Source: GlobeNewswire
URIROX-1TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population - Topline Data Expected in Second Half of 2019 -ALLN-177 has Potential to be the First FDA-Approved Treatment for Enteric Hyperoxaluria - NEWTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the initiation of the first of two anticipated Phase 3 clinical trials in support of its planned Biologic License Application (BLA) for ALLN-177 in patients with enteric hyperoxaluria. Patients with enteric hyperoxaluria suffer from an increased risk of kidney stones and kidney damage attributable to excess absorption of oxalate from the gastrointestinal tract (GI) due to chronic underlying medical or surgical conditions of the GI tract.
Show less
Read more
Impact Snapshot
Event Time:
ALNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNA alerts
High impacting Allena Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics